美国 · SEC FORM 4
Aktis Oncology, Inc.
AKTS · Nasdaq · CIK 0002035832 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
17 同一窗口内观察到的 Form 4 交易行
11 sales · 6 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-01-12 · Foley Todd.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -31.5%
- 3M
- -30.5%
- 6M
- +6.2%
- 12M
- —
波动率与流动性
- 波动率
- 68.4%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-02 · 价格来源：OpenBB/yfinance · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,715,294
- 上期报告
- 3,252,475
- 日均成交量
- 645,721
- 回补天数
- 7.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 买入 (P) | Common Stock | 1,112,777 | USD 18.00 | USD 20,029,986 | SEC 申报 ↗ |
| 2026-01-12 | Foley Todd | 买入 (P) | Common Stock | 232,870 | USD 18.00 | USD 4,191,660 | SEC 申报 ↗ |
| 2026-01-12 | EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 买入 (P) | Common Stock | 1,112,777 | USD 18.00 | USD 20,029,986 | SEC 申报 ↗ |
| 2026-01-12 | VIDA VENTURES II-A, LLC; Vida Ventures II, LLC | 买入 (P) | Common Stock | 835,000 | USD 18.00 | USD 15,030,000 | SEC 申报 ↗ |
| 2026-01-12 | Kim Helen Susan | 买入 (P) | Common Stock | 835,000 | USD 18.00 | USD 15,030,000 | SEC 申报 ↗ |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | 买入 (P) | Common Stock | 2,222,222 | USD 18.00 | USD 39,999,996 | SEC 申报 ↗ |
Form 4 申报证据
43 transaction lines in the latest 365-day window; 43 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | 卖出 (S) | Common Stock | 12,500 | USD 20.69 | USD 258,592 | SEC 申报 ↗ |
| 2026-09-23 | Czibere Akos | 期权行权／转换 (M) | Common Stock | 12,500 | USD 4.95 | USD 61,875 | SEC 申报 ↗ |
| 2026-07-20 | Herrmann Ken | 卖出 (S) | Common Stock | 4,856 | USD 24.56 | USD 119,263 | SEC 申报 ↗ |
展开近期 Form 4 证据 (23 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | 卖出 (S) | Common Stock | 12,500 | USD 20.69 | USD 258,592 | SEC 申报 ↗ |
| 2026-09-23 | Czibere Akos | 期权行权／转换 (M) | Common Stock | 12,500 | USD 4.95 | USD 61,875 | SEC 申报 ↗ |
| 2026-07-20 | Herrmann Ken | 卖出 (S) | Common Stock | 4,856 | USD 24.56 | USD 119,263 | SEC 申报 ↗ |
| 2026-07-20 | Herrmann Ken | 期权行权／转换 (M) | Common Stock | 4,856 | USD 0.59 | USD 2,859 | SEC 申报 ↗ |
| 2026-07-17 | Herrmann Ken | 卖出 (S) | Common Stock | 3,065 | USD 25.21 | USD 77,269 | SEC 申报 ↗ |
| 2026-07-17 | Herrmann Ken | 期权行权／转换 (M) | Common Stock | 3,065 | USD 0.08 | USD 245 | SEC 申报 ↗ |
| 2026-07-08 | Ron-Bigger Shulamit | 卖出 (S) | Common Stock | 50,000 | USD 27.75 | USD 1,387,604 | SEC 申报 ↗ |
| 2026-07-08 | Ron-Bigger Shulamit | 期权行权／转换 (M) | Common Stock | 50,000 | USD 3.66 | USD 183,000 | SEC 申报 ↗ |
| 2026-07-08 | Czibere Akos | 卖出 (S) | Common Stock | 50,000 | USD 27.77 | USD 1,388,686 | SEC 申报 ↗ |
| 2026-07-08 | Czibere Akos | 期权行权／转换 (M) | Common Stock | 50,000 | USD 4.95 | USD 247,500 | SEC 申报 ↗ |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | 买入 (P) | Common Stock | 1,112,777 | USD 18.00 | USD 20,029,986 | SEC 申报 ↗ |
| 2026-01-12 | GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P. | C (C) | Common Stock | 8,805,578 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | Foley Todd | 买入 (P) | Common Stock | 232,870 | USD 18.00 | USD 4,191,660 | SEC 申报 ↗ |
| 2026-01-12 | Foley Todd | C (C) | Common Stock | 4,002,533 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | 买入 (P) | Common Stock | 1,112,777 | USD 18.00 | USD 20,029,986 | SEC 申报 ↗ |
| 2026-01-12 | EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC | C (C) | Common Stock | 8,805,578 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | VIDA VENTURES II-A, LLC; Vida Ventures II, LLC | 买入 (P) | Common Stock | 835,000 | USD 18.00 | USD 15,030,000 | SEC 申报 ↗ |
| 2026-01-12 | VIDA VENTURES II-A, LLC; Vida Ventures II, LLC | C (C) | Common Stock | 4,994,212 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | Segal Lloyd Mitchell | C (C) | Common Stock | 19,631 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | Kim Helen Susan | 买入 (P) | Common Stock | 835,000 | USD 18.00 | USD 15,030,000 | SEC 申报 ↗ |
| 2026-01-12 | Kim Helen Susan | C (C) | Common Stock | 4,994,212 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | 买入 (P) | Common Stock | 2,222,222 | USD 18.00 | USD 39,999,996 | SEC 申报 ↗ |
| 2026-01-12 | EcoR1 Capital, LLC; NODELMAN OLEG | C (C) | Common Stock | 2,602,247 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AKTS |
| CIK | 0002035832 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 43 transaction lines from 2026-01-12 to 2026-09-23 9 P purchase lines · 11 S sale lines · 23 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.